Julie Russell,  —

Recent Posts

• Rituximab found as effective as cyclophosphamide in AAV children November 20, 2024
• Higher risk of thyroid disease seen with ANCA-associated vasculitis November 18, 2024
• Blood GFAP levels linked to AAV disease activity, kidney involvement November 13, 2024
• 2 self-reactive antibodies linked to higher relapse risk in AAV in study November 6, 2024
• Phase 3 trial of Tavneos enrolling children, ages 6-17, with AAV November 4, 2024
• Fasenra granted approval in EU for hard-to-treat EGPA patients October 30, 2024
• Combo maintentance therapy found more effective in severe EGPA October 28, 2024
• Alivexis’ MOD06051 shows promise as AAV therapy in rat model October 23, 2024
• Low ceruloplasmin protein linked to worse survival in anti-MPO AAV October 21, 2024
• ADX-097, potential AAV therapy, fares well in healthy volunteers October 16, 2024